相关实验视频
Updated: May 12, 2025

05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1.5K
恩多坎 - 图蒂瑞夫网络共识建议. 耐火性骨髓性甲状腺癌是什么
Hélène Lasolle1, Christine Do Cao2, Livia Lamartina3
1Department of Endocrinology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Université Lyon1, Lyon, France.
Annales d'endocrinologie
|April 27, 2025
概括
骨髓甲状腺癌 (MTC) 是一种罕见的神经内分泌瘤,通常与RET突变有关. 针对性疗法的进步为管理耐火性MTC提供了新的希望,需要个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 遗传学 遗传学 是一个
背景情况:
- 甲状腺髓性癌 (MTC) 占甲状腺癌的2-4%.
- MTC是一种神经内分泌瘤,经常与RET原基因突变相关 (胚胎细胞在20-25%,体细胞在70-80%的转移病例中).
- 局部发达和转移性MTC被称为"耐火性",具有可变的临床行为和具有挑战性的预后.
研究的目的:
- 审查耐火性髓性甲状腺癌的管理方面的最新进展.
- 突出针对性疗法和个性化治疗方法的发展.
- 提出来自ENDOCAN-TUTHYREF网络对于耐火性甲状腺癌的共识建议.
主要方法:
- 关于甲状腺髓癌的当前文献的综述.
- 分析最近的治疗进展,包括向治疗.
- 综合专家的共识和临床实践的建议.
主要成果:
- 在MTC的预后受到组织学因素 (例如,高等级的形式) 和生物标志物 (例如,酸翻倍时间) 的影响.
- 包括多酶抑制剂和选择性RET抑制剂在内的向疗法显著改善了治疗选择.
- 个性化管理,考虑到瘤分子特征和疾病进展,至关重要.
结论:
- 耐火性髓性甲状腺癌的治疗已经随着新的向疗法而发展.
- 多学科专业知识和个性化治疗计划对于最佳的患者结果至关重要.
- 协商一致的建议为管理这种罕见而复杂的癌症提供了一个框架.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92

